FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| OM | D /  | חח  |    | ۸ / ۸ |
|----|------|-----|----|-------|
|    | IB 4 | ۱PP | ĸ. | WA    |

| OMB Number:             | 3235-0287 |
|-------------------------|-----------|
| Estimated average burde | n         |
| hours per response:     | 0.5       |

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Swirsky Douglas J |             |       | 2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [ CLRB ]                                   | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner  |                                     |                                       |  |  |
|---|-------------|-------|--|--|-------------------------------------|---------------------------------------|--|--|
| (Last) (First) (Middle)                                     |             | ` '   | 3. Date of Earliest Transaction (Month/Day/Year) 06/28/2023  |  | Director Officer (give title below) | 10% Owner<br>Other (specify<br>below) |  |  |
| C/O CELLECTAR BISCIENCES, INC.  100 CAMPUS DRIVE  (Street)  |             |       | 4. If Amendment, Date of Original Filed (Month/Day/Year)   | Individual or Joint/Group Filing (Check Applicable     X Form filed by One Reporting Person     Form filed by More than One Reporting Person |                                     |                                       |  |  |
| FLORHAM<br>PARK   | AM NJ 07932 |       | Rule 10b5-1(c) Transaction Indication  Check this box to indicate that a transaction was made pursuant to a contra | act, instruction or written plan that is intended to satisfy the   |                                     |                                       |  |  |
| (City) (State) (Zip)  |             | (Zip) | ☐ affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.  |  |                                     |                                       |  |  |

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction<br>Date<br>(Month/Day/Year) | 2A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | ecution Date, Transaction I Code (Instr. |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |               |       | 5. Amount of<br>Securities<br>Beneficially Owned<br>Following Reported | 6. Ownership<br>Form: Direct (D)<br>or Indirect (I)<br>(Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|---------------------------------|--|---|--|---|---|---------------|-------|--|---|--|
|                                 |  |   | Code                                     | v | Amount  | (A) or<br>(D) | Price | Transaction(s)<br>(Instr. 3 and 4)                                     |   | (Instr. 4)                                 |

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of<br>Derivative<br>Security (Instr.<br>3) | Conversion | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date,<br>if any<br>(Month/Day/Year) | 4.<br>Transac<br>Code (In<br>8) |   | Derivative I |     | Expiration Date<br>(Month/Day/Year) |                    | 7. Title and Amount of<br>Securities Underlying<br>Derivative Security (Instr.<br>3 and 4) |                                     | Derivative | Reported                     |   | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |
|---|------------|--|---|---------------------------------|---|--------------|-----|-------------------------------------|--------------------|--|-------------------------------------|------------|------------------------------|---|--|
|   |            |  |   | Code                            | v | (A)          | (D) | Date<br>Exercisable                 | Expiration<br>Date | Title  | Amount<br>or<br>Number<br>of Shares |            | Transaction(s)<br>(Instr. 4) |   |  |
| Stock option<br>(right to buy)                      | \$1.85     | 06/28/2023                                 |   | A                               |   | 37,500       |     | (1)                                 | 06/28/2033         | Common<br>Stock  | 37,500                              | \$0        | 71,925                       | D |  |

#### **Explanation of Responses:**

1. This stock option shall vest in full on June 28, 2024, subject to the reporting person's continued service through the applicable vesting date.

/s/ Christina Blakley, attorney-infact for Douglas Swirsky 06/28/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).